Popular medications for obesity and type 2 diabetes, including semaglutide and tirzepatide, are known for their ability to lower blood sugar and reduce body weight. However, a new review suggests these drugs might also influence biological processes in the brain, potentially affecting memory and thinking abilities.
Researchers from the University of Gothenburg and the University of Copenhagen conducted this review at the invitation of the journal Science. They examined existing scientific evidence to determine if GLP-1 medications could help preserve cognitive function beyond their metabolic benefits.
Animal Studies vs Human Trials
Preclinical studies involving animals have indicated that GLP-1 medications can influence learning and memory. In contrast, research involving humans has produced less consistent findings. Some analyses of patient health records have found an association between GLP-1 treatment and a reduced risk of dementia among people with type 2 diabetes.
These observational findings are encouraging, but they cannot determine whether the medications themselves are responsible for the lower risk. More definitive results have also raised questions. In Novo Nordisk’s EVOKE and EVOKE+ clinical trials, semaglutide failed to slow the progression of early Alzheimer’s disease. Although the treatment affected several biological markers associated with Alzheimer’s, those changes did not translate into a measurable slowing of the disease.

Metabolic Health and Cognitive Function
Despite the disappointing Alzheimer’s results, researchers believe GLP-1 medications could still offer cognitive benefits to certain groups of patients. People living with obesity or type 2 diabetes sometimes experience difficulties with attention, planning, and the speed at which they process information. These cognitive problems are often associated with metabolic health and blood vessel function.
Improving blood sugar regulation, metabolism, or vascular health could potentially help preserve cognitive abilities, even if the same medications cannot slow an established neurodegenerative disease. Stina Borchers, the review’s first author and a researcher affiliated with both the University of Gothenburg and the University of Copenhagen, emphasizes the need to determine whether starting treatment earlier could make a difference.
“We need to find out whether these treatments can help people with obesity or diabetes preserve their cognitive abilities, particularly if treatment begins before cognitive problems become established,” Borchers said. “It is also important to identify which patients might benefit.”

Future Research Directions
A central unanswered question is how GLP-1 medications might influence the brain. Their potential cognitive effects could result from improvements in metabolic health, direct actions within the brain, or a combination of both. Understanding these mechanisms could help researchers identify which patients are most likely to benefit and potentially lead to medications designed specifically to support memory and other thinking abilities.
Christoffer Clemmensen, the review’s senior author and a research group leader at the University of Copenhagen, sees an opportunity to use increasingly advanced obesity treatments to explore the connection between metabolism and the brain. “Obesity medicines are becoming increasingly sophisticated, offering new opportunities to understand how metabolic regulation influences brain function,” Clemmensen said. “By disentangling the direct and indirect effects of these drugs on the brain, we may ultimately be able to develop treatments specifically aimed at preserving cognitive function.”
The researchers are calling for clinical trials that evaluate memory, attention, and other cognitive abilities beginning when patients first start treatment. Following these changes over time could help establish whether GLP-1 drugs genuinely protect brain function and clarify who might benefit most. They also stress that treatment is not without potential drawbacks, particularly for older adults and people who are physically frail. Rapid weight loss can lead to a reduction in muscle mass, which may weaken physical function and offset some of the possible benefits. Careful monitoring will therefore be essential as researchers investigate whether today’s weight loss and diabetes medications could eventually provide new ways to protect the brain.
Source: ScienceDaily

